Advertisement


Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

2024 ASCO Annual Meeting

Advertisement

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The KEYNOTE study is actually the study that established first-line combination VEGF-TKI, lenvatinib, and PD-1 inhibitor, pembrolizumab, as a standard therapy in metastatic renal cell cancer. The study has met several endpoint, progression-free survival, overall survival, and response rate showing that the combination of pembrolizumab and lenvatinib is superior to sunitinib. And here, what we did during the 2024 ASCO, great meeting by the way, we looked at baseline PD-L1 expression by immunohistochemistry, specific gene alteration by interrogating whole exome, and gene expression pattern using RNA-Seq. We did not have samples on all the patient from the full analysis, but the large subset we had on had similar baseline characteristic as the whole cohort. What we concluded is the combination of lenvatinib and pembrolizumab does work irrespective of PD-L1 immunohistochemistry. It showed that it worked and had a longer progression-free survival and improved response rate over sunitinib regardless of specific kidney cancer driver gene alteration, and these driver gene alteration are essentially the top mutated gene in kidney cancer, VHL, PBRM1, [inaudible 00:01:37], BAP1, KDM5C, but the combination is superior to sunitinib irrespective. And finally, we did look at a specific molecular subtype and gene expression, but the gene expression where the past several years reported specific to renal cell or not, but we looked at specific signature for renal cell cancer, the clusters, and universally, it showed that pembrolizumab-lenvatinib does work irrespective of any molecular subtypes, whether it's the angiogenesis subtype, the immune proliferative, et cetera. We will continue trying to find biomarkers specific to one therapy, and despite that this is a bit on the negative side, I think it's important to show that what doesn't work as biomarker as important show what does work.

Related Videos

Lung Cancer

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Narjust Florez, MD, of Dana-Farber Cancer Institute, and David R. Spigel, MD, of Sarah Cannon Research Institute, discuss phase III findings showing that durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy improved survival outcomes compared with placebo in patients with limited-stage small cell lung cancer. According to Dr. Spigel, these data support durvalumab as a new standard of care in this population (Abstract LBA5).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Gynecologic Cancers

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Advertisement

Advertisement




Advertisement